-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, F4UdtevFNauCeRMWD1wei2sWPr2Tts/CecMeQNuzhr7uOfyVOlRxHJVHlTV6n7pg zWBCX+17oFWdeCW6tOon7g== 0000950103-04-001434.txt : 20041018 0000950103-04-001434.hdr.sgml : 20041018 20041018123349 ACCESSION NUMBER: 0000950103-04-001434 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20041018 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20041018 DATE AS OF CHANGE: 20041018 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 041082669 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 BUSINESS PHONE: 1264333455 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 8-K 1 oct1804_8k-shire.htm 8-K
   
   
UNITED STATES 
SECURITIES AND EXCHANGE COMMISSION 
Washington, D.C. 20549 
   
   
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 

Date of Report (Date of earliest event reported):                     October 18, 2004

Shire Pharmaceuticals Group plc
(Exact name of registrant as specified in its charter)
 
England and Wales
(State or other jurisdiction of incorporation)

0-29630   98-0359573
     
(Commission File Number)   (IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke, Hampshire,
RG24 8EP England
(Address of principal executive offices)                                                (Zip code)

Registrant’s telephone number, including area code                     44 1256 894 000

 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
 
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



Item 8.01. Other Events

      Shire Pharmaceuticals Group plc has issued the press release attached as Exhibit 99.01 which is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

          (c) Exhibits. The following exhibit is filed herewith:

99.01 Press Release dated October 18, 2004.
   

 






SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  SHIRE PHARMACEUTICALS GROUP PLC
     
  By:

/s/ A C Russell                

   
    Name:  Angus Russell
    Title:    Chief Financial Officer

Dated: October 18, 2004




EXHIBIT INDEX

Number Description
99.01 Press Release dated October 18, 2004
   




EX-99.1 2 ex9901.htm sep2104_ex9901
Shire Pharmaceuticals Group plc
Hampshire International Business Park,
Chineham, Basingstoke RG24 8EP UK
Tel +44 1256 894000 Fax +44 1256 894708
http://www.shire.com

 

THIRD QUARTER 2004 RESULTS DATE NOTIFICATION – 4th November

Basingstoke, UK – 18 October 2004 – Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY; TSX: SHQ) will announce third quarter 2004 earnings on Thursday, 4 November 2004.

  Results announcement time:   12:00 GMT / 07:00 ET
  Conference call time:   14:00 GMT / 09:00 ET

Live conference call:
Matthew Emmens, Chief Executive Officer, Angus Russell, Chief Financial Officer and Greg Flexter, EVP and General Manager, North America will host the live analyst and investor conference call at 14:00 GMT/09:00 ET.

The details of the conference call are as follows:

  UK dial in   +44 (0) 20 7984 7576
  US / Canada dial in   +1 718 354 1157
  Password   Shire Pharmaceuticals

Live Webcast:
The call will also be available live over the Internet via audio webcast, accessible through www.shire.com in the investor relations section. A slide presentation to accompany the call will also be available on the Shire website.

Replay:
A replay of the presentation will be available for 1 week. Details are as follows:

  UK dial in  

+44 (0) 20 7984 7578

  Pin code  

395273

  US dial in  

+1 718 354 1112

  Pin code  

395273

  Webcast Replay  

www.shire.com, in the investor relations section

If you have any problems accessing this, please contact: Souheil Salah on: +44 (0) 1256 894160

End

For further information please contact:

Souheil Salah – Investor Relations  

+44 (0)1256 894 160





Notes to editors

Shire Pharmaceuticals Group plc

Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.

For further information on Shire, please visit the Company’s website: www.shire.com.

GRAPHIC 3 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!`0$!+`$L``#_VP!#``,"`@,"`@,#`P,$`P,$!0@%!00$ M!0H'!P8(#`H,#`L*"PL-#A(0#0X1#@L+$!80$1,4%145#`\7&!84&!(4%13_ MVP!#`0,$!`4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P``1"`"[`5\#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]4Z***`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`&MG!QUQ7'S^(-1 MT.S,M_#YM["=(XYX@')ADWQLI'!#?TK7@N8KI-\,J2IG&Y&##]*X;4 M+%["2\BC5M-TU0#!ON#V5`.!GGH!UK3\->(;,+;6D-@]C;S%EA8L&5V'4 M''(;CO3E'J@.@OH99X62*5HI#RK#./QQVKF+O4M3TJSE@=_/U-HO.*J&\M8P M?FP_25) MOWB1[3%<`$+,K#(/)/(Z'FMW.:\^U>T:QU,VKN\-G#M^QVBLR),.=PW@\-D] MZZSPQ]M&CQ?;]WVC+<2'Y@N?E!]\8JYI?$@-:L_4;V>TN+5(;22Y25]CLAP( MQCJ:T*0BLP$4_*,\$CH:6J5]#>2RVQMKB.&)7S,KINWKZ#TI-4UBVT:S:>Y< M(@'"]V/H!0!>!![TMQ;'2NWJ"[LH;ZW>&=!)&XVD&J3L!S7AKQ!-<:A)8RS/=QQ MIN:XDCV-&^<%&QP?J*ZH-NY'(KA?$NFOI5D;&"W)TY8UDB*1E_WJMG#D<_,# MWJ]H>KVNAQO!/.P\S$ZVJHSM;*1DJV,X&?RJI0YE>('5N@8CJ!-BL^^T M*TU&^AN;F+SFB4JJ/RG/?;TS6@3@9H!!&:$[;`<'KFGV&BW<*1-<7MP6\RWT ML.3&K=FQV%=1HNL/J4+>?;R6MQ&0LB.A`SC/RGN/>KCVL2RM.L:?:"NW>1SC ML,^F:\[?2KZ02.(YY=89OG+[D:)MW#(?NE<=1GT^E:I\ZLP/3`:6L:Q\1V=Q M<-;+/NG4["2I"LX`R%)X)]JV!S65FMP%HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`:1U MKE+WPEJ@UE-_:HN_M<@A$>PVV!M)S]ZK*7,#OAQX7^#EIXFO=)ADL+?4[V76-1>6>24>:RC>PW$D#"YP*[JFLH8$&A-I M6Z`?#7[2?[4=[X_^W>%O`MUJ6B^"[&]CL?%GCR&SE:.Q1FVM$@"[O7)OAK;^+(_B)X8T&R@N]*\2JQ>6*-VVBTG?&'=&Y9WG@6%=L[-]XL.`Q;H2>M?&7B"R^()DO_'WAVUT+ MX!^!?"MQ+/!INJV@M_[8E7=&TEY';8_=D_*JC<3G*AL@UZU.5.M2=&,;?Y_= M?[C%IQ=[GW#5'6=-_M73;BU$C1&5P*>!G&:\R<)4YQQ( ML9[*_D>_BB\V5EFM8(&)\R>-?O>V1P&/$=QJS"*[@5)"AD#PYV<'#*<] M&!K6U32X-4@$S\+Z9(S2LL(9I'DE;+,3UIM\R\QFK MN%*.E<&OB'4==U%I+2X33XH!YD4-P,&=?4^U=7H&KKK>FQ72H8MV59#S@@X. M#Z4I0<=P-*BD!S2U`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`"$9%5(-+M;.YFN884CEF(,C MJ.6QTJY2$9H`IZ7JL>JPO)''+&$F:IKEGHR(UW,(@[;5!ZGW^@J MU17]ND]O(LL3C*NIR#7F/[1?POV@+OXO37=AJFG65O>0Z=9ZM;W^D3O-9WUMI>&?"_A&]L]2LBFL/:ZCXHL9RWVM8IE"CS(I MG)$:8&"21QNKTX.&,CROX_Z^\PU@_(_1I6W5#>6<5]"T4\231-U1QD&O.?V? M!XPB^'R)XROH]2N1<.=.OLCSKC3R%:W>?Y5_>[3AN!R/4UWUGK^F:A?7EE;: MC:7-Y9,J75O#.KR0,5W`.H.5)4@@'''->3*+BVNQNF87B;1S=W$<]U'$-*L8 MC(449:3C[OL.*J:7XI-D]I;_`&"WM(7D5$MT)$B*XRK],,#[5V>G MVK;O,0/./6KE>=Z9K$>CW=VMK:_:I!N::[N)=CS%3\^S(QQZ9KOK:X6Z@CE0 MG9(H92?0C-3*/*!-129S2U(!1110`4444`%%%%`!1110`4444`%%%%`!1110 M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!5:^CFFM98[>7R)F7 M"2%=VT^N*LTF!Z4`[1M6U6ZD$22%S&=QS@+@_*!BM'PWX@GO[ MG['=&)Y3$9/W08%,'!1PV2#S^-;NI:=!J=L89TW+D,"#@J1T(/8UR?B2U728 M)K>.1K7<#@^XK%T/7H-,L4FN[EH[6ZVM;),S.Z\?./7`/?WKJXI8 MYD#QNKHPR&4Y!'UJ&G%B/`_VB_&/Q.76-'\!_##0IH=3UF,RS>+;I0;+385. M'&<']Y@@C([C`8GY?D6UEU?X5:I%I?@G2_%#?M#Z;JGD:^\3R7]EK$,I,@DN M'.5$;J5920K+SDD_-7Z:3Q[T(48)!&1P17Q1\??AWJ'P(TC2;+PKXKOO#3^- M-H/0XY'YYJP1D=<9KXM_9X^,&L>`?^$[U'QMK.IK\/M(L+1Q MJ6O:B;Y7OB&\Q=/N>3=02*`Z\D@D+@'(KZ1^"OQ+N?BWX*@\32Z#>^';:[GE M%G;W[#S9K8,1',5'W=XYP?S(P3Y];#RI-RW1K&:9N:OX:M(;2ZDV3W,`W3FR M!!4OURIQE?P-8P\274F1FLXR[EFM;W<-R&\J5)"IPP1@<'WQ5BO.=,DMM M#D>]G$UA;P7#+#NBVR7"L"=A'?:<8)KM-*UVVU9I$C$L4T>-\4Z;&`/0X]*F M4;;`:5%(#D4M2`4444`%%%%`!17(_%+XACX7>$I-?;P_JOB2*.>&![/1FMA. M/,<(K?Z1-"FW,/VDKSP%X1FU_7/A'X^LX8+N"UEME&E321 MK*VU)V=+]HA%O.UCORGWG"H0U`'M-%>1^+?VA'\)7'B=&^'/B_4[;0)[2VFO M+%M,\FXDN-FU8C)>H25,B!@P4C>IP002SQC^T0?!>L^)].N/AUXMOCX?T2/Q M!<7%G)I?ERVS'#>7OO58NA6;<&5?]0^TMNCW@'K]%>%M^U-(GB"[TAOA/X[, M]CI%IKM[)&=(D6VLK@RA)2JZ@7?#6\ZE(U=\Q'"D,A;5U/\`:*%OXEO-'TKX M>>+O$OE:=9:K;7FE'3?)OH+J58HFB$UY&Z_,7W>:B!1$Y)QM+`'K]%>6_!_X M\#XPRRF'P+XI\,V2M>Q1W^M_8##+-:71M;B(&VNIF#+*K#YE4,%)4L.:A3]I M'PZFK:G;7NE:YIMA;VMU>6.KW%JC6NKI;R+'.+79(S[E=T4+*D9?=NC#J"P` M/6**XOX?_%&S\=Z=K,L^D:IX5U#1;@VVIZ5KR1)<6C>6LJL6BDDB=&C=&#QR M,O)!(964<[HW[1FA:KX:\0:W-H?B+3H-)L%UB.VGL!+-9!AE##T(S3J*`.+US0= M0:^WVD?GL;A9H9S)@P#`#J1W4@=JZ*T@M?#VF!/,$5M%EMTC=,DG^9Z5I5SO MB'PV==OH6N;DKI\2EFA48);US]/\\U=^:R8$FD^+K75IVB"M;L2?)\WCSE_O M+_A6O/:175N\4R+)&XPR,H((]"#7GBM)J5I$)KZ&/2;"Z'EWLJXD<#H!_P#6 MKT"QU*VU*#S;699H\X+(>AHG'EU0'RI^TO\`"-O"T?B/XLW(N/&C>'K*/_A& M_"DMNOV#3)"0KW#1*/WH3/F\C@(V$M+O?%%YXYBUB[ MG759X8(KC1C:B+S$NK.YB4>3LW*CQ2<@^S+7W)(@G4J0&0C!&\6:/XKM&N=$U:PUBV1BC36-RDR*PZJ64D9]JV",C%?G]\% MO%5Y\._$6H_%W5=.B\+?#-++^R]^GZ0 M[4#,,L?:I@);V]GMHS9Z/>P M6=PL:SI([K-+/`$(5"`5<.&*D>HXK2$\167@O5/#&G_"#QD-,UNX%I,_C#Q' M8:O-"DR>7//.9-1F>2!$"D()7=CN4(BA2?H6B@#Y,O\`PO\`$31_@]XI^%3? M#OQ/XETW3KV"#1?$EIK6G0W6K6(N(Y6DE=KV*6.X4!U\SY6&/A[X[UNPUSP3'I%G=ZMXK@U,S7C&;*/"=W-Y'@O3=)NO$5@] MA%I]U?P&66800BX\Y$+3;5W1(,HWW5VD^]44`>0?LM:3XB\/_#*[T[Q/X6U# MPIJ(\0:U?);:A<6DS20W>I7-Y$RM;3RKPEPJL"00Z/@%=K-P4/P$O=0G\2W6 MI:=XN;PG9VFIVNC>$GU+3VO&DNI4>26UD1E6)08MT(GN&(\T[O+"J@^G**`/ M%?AY\._$?AWPUKD/B*;6=?UOQG<,E[>3SV3&Q\ MR?`!1=XQ-`\+>-YO#6NWVJ^$)[+4;#P<(TA8^ M5Y?FNCXW;UCP`?H6B@#FOAK'?0?#WPW#J6F7&C:A#IT$-Q873Q/+`ZH%96:) MW0\CJK$>]=+110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!2% M0?QI:*`.6\1^&C>SVAXR"/<4I1MJ@/!OVBOV==;^(6OG7?" MTFCW$MSH4WAZ_P!%U\2K:30,YDCF1HP2DL;G(.TCITQFO$M+^,&O_!7Q+J.B M^'M!TR^UBTDL-,\:>.-;DN$L;F_2VQ"N$!,((&SSW&TL06QD$_?.HD.JQ:;=F*WU:%1@1741!61=I*G@$@D9KLH8F*3A6 M5XF4H.]XG0_!7XGP?&3X8:!XQMK*33HM4B9_LLSAVC979&&X<,-R'!XR,'`S M7=5QNB:OX/\`!.HZ3\/]-NM-TN^BLO-LM#A<)(+9#C*IUP/7V)[&NRKBFES- MI63V-%M8KW%C!5*6:,R>;M^08[9]:NTF M.:D8M%%%`!1110`4444`)G%&10W2FT`.S1N`IA.!TS7S[^U=^V#H?[+>EZ5] MITQO$6MZHSK;:;;W:0F-5`_>2DY94.<`A3DC%:TJ4ZTU3IJ[9$YQIQYI;'T' MYB^OZ4N\>M?DWKO_``4\^,OC2^^S^$]`TC22>5AM+*6]N,=R2Q(('KL%8/B? M_@HC\=M%2YT=_%&A75T54G4+'3HF:(D`X4D;RLDQ;=K+[S@>84 M4KG[!+(K=#F@.I[U^9G[*/Q*N?VG]=GT'Q+\8/B5H/BR*`SK%9:S9VUK=XQN M$*+"K[N<[0#P#SQ7U1%X'\??`>]M-:MOB5JWCOPI]KM[:^T;Q3%'/?BYH7@=? MA]+H;:IYW^FMJPG\ORXGD^YY*YSLQU[TH8'$SH^WC#W>^@Y8BG&:IMZGVOD4 M9%-HKA.H=D4;A33VKY:_:S_;?C_9;\5:'HTG@]O$AU.S:[\Y=2^S>7B0IMQY M3YZ9SD5K1HU,1-4Z2NS*I4C2BY2V/J?(HR*^2/V5/V]HOVG?B1>>$T\$OX<: MWTZ34/M;:G]I#!)(TV[?*3'^LZY[5]:U5:A4P\^2JK,*=2-6/-%W0[(HR*;1 M6!J.R*,BFT4`.R*,BFT4`.R**;3ATH`6BBB@`HHHH`3&:",BEHI6`QM;T!=2 MEBN8]HNH494\Q0R,".0P-C_:?[.MOMA!N M?+'F<M?[8CTU7\RY8%F"_P`#//UIF[Z(RG-0W/4?CC^T]X2^"!M=-NVN=>\6ZAM&G> M&-'C,U]=EF*KA1PJD@_,2,[3@$C%?F)\>?#:Q^.;_P`B7*27EE;9)CCNK@[DM4"[0%573$CE4;K&GH@/U)P*_+G]L_]E_Q/\#/B1J^IRQ7>K>$=7NI;FQUE MRT[#<4L\S'S!C>"!M)7:.* MJ_M*?\$T(_A3\/M6\6^#_%-]K8TU!//IFHVP:=X]P!:-X\`L-V=I3D`\YQ7Q MOX!^*'BWX6:I_:/A'Q'J/A^Z)!)8EX9KVR,,K?0PN@!_X":]JKAL?1K>TP\[Q['GPK8>I#DJ+7N?,FB:1X MLT#5[+4]+TW5[+4K*5;BVN8;20/%(IW*P.WL1FOW0^%'B*;XT?!7PEKVKV9L M+G5;.VN[RT*D!9596=-K#.TNAZ\X-?.WP%_X*:>!?B;=V>C>,+%_`^N7#B%) M97\VPD<\#][@%,G^^N!TW5]G1.LD:LI!4C(*G@U\[FV)JUI1C7IK@J4( M)RA*Z/ST_P""OJC_`(1WX8\?\OE_U_ZYPU\O?\$\CM_:^\!]^+T_^2<]?47_ M``5^_P"1=^&/_7Y?_P#HN&OSU^'6N>)=!\7V4_@][F/Q'<+)8VALA^_+3QM" M1'CD,5<@$#;SQ=JN@Q7%K!$;N\2WOTGNH4QN=G3/)' M5MI/<\UXIX)\::M\._%^D^)-"NGM-5TRX2X@E5B,E3G:W/*MR".X)%>9')J% M:DY4*MVON.MYA.$[5(61_0Z#G_ZXKXO_`&X?V??`?QB\;^'-0\7?%W2?AS=6 M>GO;PV6I"$M.AD+&1=\T9QGC@$<=:^K_`(<^+8?'_@'P[XGMX_*AUC3K?4$C M)R4$L:OC\-V*_-7_`(*X@#XL^!A@<:+)V_Z;FO'RRG.6+4(RY7KJ=^+G%4'* M2NCV?]BK]F[X>?"/XMWVM>%/C-HWQ#U&329;1],T_P`G?'&TL3&4[)W.`4`Z M#[W6OMO4M2M='T^YO;ZXBL[*VC::>XG<(D2*,LS,>```22:_)K_@E)_R)+=&B MPEG91(H5(E=V"+@8^7.XYR%?'&G>--`N-!N[C48)8$F9&$R"+!961BIYXZFOES]NS]M'7/B9XVU?P1X M3U6;3O!&F3&UG:T8QOJ4Z$B1G<')B#9`4<,!DYR`/(AESQ&*E0H2O%=3OEBO M9T54J+5]#]$O%7[7GP;\&:C-8:M\1-$BO86*RP6\YN&C/HWE!L'V-:WP_P#V MCOAE\4KW[%X6\;:1K%^1D6<5P%G88SQ&V&/X"ORV_9B_X)^^)_VAO#!\3WFK MQ>$/#LC,EG/+;?:9KLJQ#,B!TP@(QN)Y(.!CFO.OVD/V:_%/[*_CFQL-4OH[ MNVO$:?3-9L"\8D"L`>#S'(N5)&3]X8/IZ:RK"3FZ$:OOK[CC>,KI*I*'NG[K M!@S$`]*>.@KX?_X)P_M8:M\8-)U#P)XMN&O?$>BVRW%KJ,SDRWEKN"GS,]71 MF4;OXE9<\@D_;ZG*@U\YBE4C5@IQ'4445S&H4444`%%%%`!2 M8S2T4`-9%8Y*@D="15!+ZX;57MC:LMN(PRW&X8))Z8]>M:--:@!01G&:",U0 MT^WO8;FZ:ZN5GB=]T**F"@]#5Y'#\@@CU!S0`V:+S873)7<,;E."/<5DZ1X6 ML])>.5%:2Y4L3<.V7?/!SZUM44+0`HHHH`****`"F2,%(YQFGU%-TQ0)GQ1^ MV)\"=;\4:LL[Z9I%K)>7(MH] M\GEH,L57(SP#7RQJ'_!3KX&ZK9S6=[:Z_U?A3\>/@9XB_9^\?WWAG MQ!;R;$=FLM1*$17\.?EE0]#QU`^Z#_P"RK'54=HIM-EDL74J[(P:%',:G_>")I$T+6$4RS$#.R.=0JY/0!E`SC+#K7S5^SQ^VI\0O MV;]-N-)T*2RU;0))#*-*U6%I(HI"?F:-E963/<9*D\XSDUW_`,3/^"FOQ6^( M'ARZT>RM])\(QW*F.6]TE)#;Z'& MZ^%J0O..I\C,I#-&PPPX*MV-?M!_P3H\;ZAXT_9:\.G4YGN)],N+C3$FD.28 MHW_=@G_90JOT45^-^@:!J7BO6K32=(LI]2U2\E6*"UMD+R2,QP`!_GWQUK]R M_P!DSX.7'P*^`OACPEJ!B.KPQO<:@T+;D^T2NSNH/\07<$![A0:K/YP]A&#^ M*Y&6*7M&TM#Y2_X*_?\`(O?#$?\`3Y?_`/HN&OE?_@GY9PWO[7G@!9D$BQO= MRJ".CK:3$'\#7U1_P5^.?#WPQ_Z_+_\`]%Q5\N_\$\3_`,9?>`_I>_\`I'/5 MX/3*7Z2_-DXC7'+U1^R?C2!+CPAKB.H=&L)U*MT(,9R*_G>'^K'T%?T2^+O^ M14UGG'^A3?\`H#5_.TO^K'TKFX!^]G[+/\`R;7\+_\`L6M/_P#2 M=*^!?^"N7_)6O`__`&!9/_1[5]]?LLD?\,U_"_G_`)EO3_\`TG2O@7_@KCS\ M6O`__8%D_P#1[5YN5_\`(Q^;.O&?[K]QS?\`P2D_Y.2UC_L6[G_THM:_3/X] M?\D,^(?_`&+NH?\`I-)7YF?\$H_^3DM8_P"Q;N?_`$HMJ_3/X]?\D,^(7_8N MZA_Z324\X_W]?(,%_NK^9^`!X4\=J_>_]FSP9I/@7X%^"-+T:SCLK3^R;:X9 M8QR\LD:O)(WJS,S,?-?#7B?Q!;64C2VZW%K`OE, M1M8@H%/(Q^5=%^R]_P`%%]6^!'@FW\(>(O#[>*M$L25L+B&Y$$]M&3GRSE6$ MB@D[>00#C)`%9_Q\_P""D'Q`^)VJ6G_"&R7?P\T>T#$Q6=R);BY8]&E?:``` M.%`QR22>*]6V+6(:A1BO[QQ.5'V?O5&_(WOV*_V=OB_\+_VEO!^NZOX)U?1M M%1KB&^O+B-1&L3V\@`;G^_L_&OUF0?*/I7PK_P`$[9/C'\1);_QYX^\5ZU?^ M%&@:VTFSOYN+J0L-\^W^ZH4J#T)9L?=S7W4G""OELUJSJXC]Y:ZTTV/9P4%" ME[M[/N.HHHKQST`HHHH`****`"BBB@`HHHH`1AD$>M9MK96GAS3I0F8K9-TK MDDL1W)K3IKJ'4AAD'J#0!P&HZ]-KUW;J;B31]+;+Q7+J1YKCD.0QF5/NR8_B%7=62&/39M]F;N-%R+=4#;O3`K'T&VU*/4H[BZ MDAM()8RJ:>@^Z.HQVSZUKHXZ`=111160!1110`5'(A;XN\&Z5K5S@#[7-#LN,`8QYJX?'MG%8_A3]DOX2^#"#I?@?3D`Z1 MW327*#Z+*S@?E7K]%:JK44>7F=O4S]G"][&;I'A[3M`@%OIEC:Z=;#I#:PK$ M@_!<#]*S_&WP^\.?$?1Y=)\3Z'8Z[IL@(-O?0+(H/J,CY3[C!%=%14*3B[IZ MEM)JS1\FW_\`P3%^!UY=R31:3JUBCG/D6^JRE%^F_<<>V:@3_@E[\$5D5C9Z MXP!R5.J,`?R`KZYHKL^O8K_GX_O.?ZM1?V4>>_"SX!^`O@KIHL_!OAFRT?*[ M9+E$WW,O^_,V7;\37?A<#&*?17)* M&[+Q%'8,[VJW@)$1<`,1@CKM'Y5S_@G]EGX5?#GQ'9Z_X;\#Z7I&LVF_R+RW M1@\>Y2K8))ZJQ%>KT5:K55'D4G;M?0ETX-\S6I6NK..]MI;>9!)%*A1U)X92 M,$?C7BW_``Q)\#@!CX::)_W[;_XJO<:6IA5J4_X,O">G^(+RUB M,$$UXI9HTSG:,$<9.:]$HI1G.$N:+:8W%-6:T/-/A[^SE\./A1KDFL^$?"&G M:#JQJ_16:=M44U?<^;/%?_!/#X%>+-1DOI/! MITRXD)9QI5[-:QD^T:MM'X`5J?#S]A;X+?#341J&E^"K6\OT.4GU>62^V>ZK M*S*#[AB4J+<.ICQP=P`_I6A M11L`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%% M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444 #`?_9 ` end -----END PRIVACY-ENHANCED MESSAGE-----